FDA Approves CAR-T Therapy Tisagenlecleucel for B-Cell Acute Lymphoblastic Leukemia – Cancer Therapy Advisor
Cancer Therapy Advisor |
FDA Approves CAR–T Therapy Tisagenlecleucel for B-Cell Acute Lymphoblastic Leukemia
Cancer Therapy Advisor This approval marks the first chimeric antigen receptor T cell (CAR-T) therapy, which utilizes the patients' own genetically-modified T–cells to target the CD19 antigen on the surface of leukemia cells. Once modified, the cells are injected back into … |
